Abstract:
Cutaneous metastases of ovarian cancer are rare and often have poor prognosis. We report a case of a 62-year-old woman with recurrent low-grade serous ovarian cancer, who presented with lung, brain, and multiple skin (nasal and anterior chest wall) metastases approximately six months after the initial diagnosis. In this case, Nijmegen breakage syndrome carrier status caused by RAD50 heterozygous mutation and previous bevacizumab therapy could be the predisposing factor for cutaneous metastases. The patient was treated with local radiotherapy (nasal skin and brain, 30Gy/6f/1.2W) and three courses of chemotherapy with albumin-bound paclitaxel and carboplatin, resulting in drastic remission of the cutaneous metastases. Unfortunately, treatment interruption resulted in rapid tumor progression, followed by death. This case represents an interesting example of cutaneous metastasis of ovarian cancer with rare clinical manifestations, unique genetic mutations, and reasonable response to treatment. Chemoradiotherapy might be an appropriate option for cutaneous metastases of ovarian cancer. Nevertheless, we still hope to find out the best treatment strategy after collecting and reviewing more cases in the future.
摘要:
卵巢癌的皮肤转移很少见,预后通常较差。我们报告了一例62岁女性复发性低度浆液性卵巢癌,出现肺的人,大脑,和多个皮肤(鼻和前胸壁)转移约6个月后的初步诊断。在这种情况下,由RAD50杂合突变和先前的贝伐单抗治疗引起的Nijmegen断裂综合征携带者状态可能是皮肤转移的诱发因素。患者接受了局部放疗(鼻部皮肤和脑部,30Gy/6f/1.2W)和三个疗程的白蛋白结合型紫杉醇和卡铂化疗,导致皮肤转移的急剧缓解。不幸的是,治疗中断导致肿瘤快速进展,其次是死亡。这个病例代表了卵巢癌皮肤转移的一个有趣的例子,具有罕见的临床表现,独特的基因突变,对治疗的合理反应。放化疗可能是卵巢癌皮肤转移的合适选择。然而,我们仍然希望在将来收集和审查更多病例后找出最佳治疗策略。